Replies to post #338192 on Avid Bioservices Inc (CDMO)

[Amrsto1000]

ENHANZE® Drives 86% Year-over-year and 34% Sequential Growth in Royalties in the Fourth Quarter -
- 2021 Revenue Guidance of $375 Million to $395 Million Representing 40% to 48% Growth over 2020 Revenue -
- 2021 Royalties Projected to Double versus 2020 Royalties -
- 2021 EPS Guidance of $1.40 to $1.55 Representing 54%-70% Growth over 2020 EPS -

SAN DIEGO, Feb. 23, 2021 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO) today reported financial results for the fourth quarter and full year ended December 31, 2020